Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chronic Hepatitis C
Interventions
PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Hepatitis C, Chronic
Interventions
midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
La Mesa, California • Rockville, Maryland • Marlton, New Jersey + 2 more
Conditions
Healthy
Interventions
BI 207127 NA
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Hepatitis C, Chronic
Interventions
BI 207127, BI 201335, Ribavirin, BI 207217
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 9 more
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, BI 207127 high dose, Faldaprevir, BI 207127 low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
La Mesa, California • San Diego, California • DeLand, Florida + 3 more
Conditions
Hepatitis C, Chronic
Interventions
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
31
States / cities
North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin (RBV), BI 201335 (Faldaprevir), BI 207127, Faldaprevir (BI 201335)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
24
States / cities
Dothan, Alabama • Chula Vista, California • La Mesa, California + 19 more